Pfizer Says U.S. Is Probing Lipitor Price
Pfizer Inc. said the Justice Department is investigating pricing on its cholesterol drug Lipitor from 1998 through 2001.
New York-based Pfizer said in a Securities and Exchange Commission filing that the Justice Department is examining whether grants to health plans and pharmacy benefit managers should qualify as rebates.
That would entitle the government to a bigger discount on the drug under best-price rules for Medicaid. The investigation is among several recent federal inquiries and state and consumer lawsuits on drug pricing.
Pfizer fell 88 cents to $36.49 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
